2024
October
AACR Tumor Immunology and Immunotherapy Meeting 2024
October 30, 2024
This week’s extensive special feature covers select talks from the AACR Tumor Immunology and Immunotherapy Meeting 2024 in Boston. We have organized the content by topics below. Keynote lecturesSusan KaechTon Schumacher BiomarkersCornelis JM Melief Neoantigen vaccinesVinod BalachandranPablo GuaspLorenzo De MarcoRobert D Schreiber Tumor immune environmentSam NuttThomas GajewskiRoberta Zappasodi AdjuvantsArthur KreigPolina Weitzenfeld Keynote lectures...
Understanding histone lactylation to enhance immunotherapy
October 23, 2024
Metabolic changes in T cells are often accompanied by changes in gene expression, functionality, and differentiation state. To better understand the connections between some of these changes, Raychaudhuri and Singh et al. recently explored how metabolic pathways that increase lactate production can lead to changes in lactylation – a histone modification of lysine...
Tracking the neoantigen landscape in response to checkpoint blockade
October 16, 2024
While it is known that neoantigen immunoediting plays a role in immune checkpoint blockade (ICB) efficacy, it is unclear how neoantigen recognition by T cells impacts tumor presentation of antigens in response to ICB. Alban and Riaz et al. evaluated changes in tumors in relation to neoantigen reactivity and therapy response to address...
A type 2 cytokine fusion with type 1 effects – using IL-4 to enhance antitumor immunity
October 9, 2024
Interleukin 4 (IL-4), a cytokine typically associated with humoral (type 2) immune responses, has recently been shown to promote survival in T and B cells. Studying whether IL-4 could be exploited to enhance cancer immunotherapy, Feng and Bai et al. developed a fusion protein of IL-4 and a mutant IgG2a antibody (Fc–IL-4), and...
Unmasking higher immunotherapy efficacy potential with a new IL-2 therapy
October 2, 2024
Attempts to avoid systemic toxicity and Treg activation induced by IL-2-directed therapy has resulted in the development of various engineered immunotherapy products that specifically target IL-2Rβ/γ on CD8+ T cells and NK cells. However, these products have, so far, shown limited clinical efficacy. In a recent paper published in Cell Reports Medicine, Wu...
